TPCN2 and cancer: Carriage of TPCN2 rs3750965:GG was associated with an increased risk of cancer recurrence susceptibility in patients with prostate cancer (OR: 1.07, 95% CI: 0.94–1.22, P = 0.018* vs. A/A), whereas carriage of P2RX4 rs25644:GG was associated with a decreased risk of cancer recurrence susceptibility (OR: 0.52, 95% CI: 0.28–0.96, P = 0.038* vs. A/A), after adjusting for age as well as sex and ethnicity (see Table 5 and Fig. 2d).